Q1 EPS Estimates for Prime Medicine Lifted by HC Wainwright

Prime Medicine, Inc. (NYSE:PRME) – Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for Prime Medicine in a research note issued on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their previous estimate of ($0.36). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.28) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.75) EPS.

Several other research analysts have also weighed in on PRME. StockNews.com raised shares of Prime Medicine to a “sell” rating in a research note on Tuesday, February 11th. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Prime Medicine in a research report on Monday. Citizens Jmp raised Prime Medicine to a “strong-buy” rating in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating and set a $18.00 price target on shares of Prime Medicine in a research report on Tuesday, December 3rd. Finally, Wedbush reiterated an “outperform” rating and issued a $12.00 price objective on shares of Prime Medicine in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.13.

Prime Medicine Trading Up 5.0 %

NYSE PRME opened at $2.31 on Thursday. The stock has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $3.38. The stock has a market cap of $302.98 million, a PE ratio of -1.13 and a beta of 1.86. Prime Medicine has a twelve month low of $2.12 and a twelve month high of $8.58.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PRME. Vestal Point Capital LP boosted its holdings in Prime Medicine by 137.8% in the third quarter. Vestal Point Capital LP now owns 1,070,000 shares of the company’s stock valued at $4,141,000 after purchasing an additional 620,000 shares in the last quarter. Barclays PLC lifted its position in shares of Prime Medicine by 343.3% during the 3rd quarter. Barclays PLC now owns 84,697 shares of the company’s stock worth $328,000 after buying an additional 65,593 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Prime Medicine by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,359,979 shares of the company’s stock valued at $5,264,000 after buying an additional 63,456 shares in the last quarter. State Street Corp grew its position in shares of Prime Medicine by 3.9% in the 3rd quarter. State Street Corp now owns 1,146,949 shares of the company’s stock valued at $4,439,000 after buying an additional 43,086 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Prime Medicine during the 3rd quarter worth $55,000. 70.37% of the stock is owned by institutional investors and hedge funds.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.